Loading...
Developing therapies for heart failure with preserved ejection fraction: Current state and future directions
Butler, Javed Fonarow, Gregg C. Zile, Michael R. Lam, Carolyn S. Roessig, Lothar Schelbert, Erik B. Shah, Sanjiv J. Ahmed, Ali Bonow, Robert O. Cleland, John G. F.
Butler, Javed
Fonarow, Gregg C.
Zile, Michael R.
Lam, Carolyn S.
Roessig, Lothar
Schelbert, Erik B.
Shah, Sanjiv J.
Ahmed, Ali
Bonow, Robert O.
Cleland, John G. F.
Author
Butler, Javed
Fonarow, Gregg C.
Zile, Michael R.
Lam, Carolyn S.
Roessig, Lothar
Schelbert, Erik B.
Shah, Sanjiv J.
Ahmed, Ali
Bonow, Robert O.
Cleland, John G. F.
Cody, Robert J.
Chioncel, Ovidiu
Collins, Sean P.
Dunnmon, Preston M.
Filippatos, Gerasimos S.
Lefkowitz, Martin P.
Marti, Catherine N.
McMurray, John J.
Misselwitz, Frank
Nodari, Savina
O'Connor, Christopher M.
Pfeffer, Marc A.
Pieske, Burkert
Pitt, Bertram
Rosano, Giuseppe
Sabbah, Hani N.
Senni, Michele
Solomon, Scott D.
Stockbridge, Norman L.
Teerlink, John R.
Georgiopoulou, Vasiliki V.
Gheorghiade, Mihai
Fonarow, Gregg C.
Zile, Michael R.
Lam, Carolyn S.
Roessig, Lothar
Schelbert, Erik B.
Shah, Sanjiv J.
Ahmed, Ali
Bonow, Robert O.
Cleland, John G. F.
Cody, Robert J.
Chioncel, Ovidiu
Collins, Sean P.
Dunnmon, Preston M.
Filippatos, Gerasimos S.
Lefkowitz, Martin P.
Marti, Catherine N.
McMurray, John J.
Misselwitz, Frank
Nodari, Savina
O'Connor, Christopher M.
Pfeffer, Marc A.
Pieske, Burkert
Pitt, Bertram
Rosano, Giuseppe
Sabbah, Hani N.
Senni, Michele
Solomon, Scott D.
Stockbridge, Norman L.
Teerlink, John R.
Georgiopoulou, Vasiliki V.
Gheorghiade, Mihai
Abstract
The burden of heart failure with preserved ejection fraction (HFpEF) is considerable and is projected to worsen. To date, there are no approved therapies available for reducing mortality or hospitalizations for these patients. The pathophysiology of HFpEF is complex and includes alterations in cardiac structure and function, systemic and pulmonary vascular abnormalities, end-organ involvement, and comorbidities. There remain major gaps in our understanding of HFpEF pathophysiology. To facilitate a discussion of how to proceed effectively in future with development of therapies for HFpEF, a meeting was facilitated by the Food and Drug Administration and included representatives from academia, industry, and regulatory agencies. This document summarizes the proceedings from this meeting.
Keywords
epidemiology, heart failure, preserved ejection fraction, prognosis, treatment
Date
2014
Type
Journal article
Journal
JACC: Heart Failure
Book
Volume
2
Issue
2
Page Range
97-112
Article Number
ACU Department
Collections
Relation URI
Source URL
Event URL
Open Access Status
Open access
License
File Access
Controlled